Please login to the form below

Not currently logged in
Email:
Password:

ADC Therapeutics expands team

Appointments preceed its first antibody drug conjugate trials

edit-ADC_Therapeutics_Logo_RGBADC Therapeutics has significantly expanded its team head of putting its first antibody drug conjugates (ADCs) into clinical development.

Oncology drug development company's new team members include Jay Feingold joins as CMO and head of oncology clinical development.

He has more than 25 years of industry, academic and medical experience and most recently worked as VP US medical affairs and chairman global medical affairs oversight committee at Daiichi Sankyo.

ADC has also appointed Michael Mulkerrin as head of CMC (chemistry manufacturing and control).

He has more than 20 years of industry experience in biologics manufacturing and recently work as VP process development and manufacturing at OncoMed and has had prior senior roles at Abgenix, Amgen and Genentech.

Additionally, Simon Chivers joins ADC as head of toxicology, Lisa Skelton is appointed as senior project manager for lead programme ADCT-301, Karin Havenith join as senior bioanalytical scientist, Francesca Zammarchi will work as cancer biologist, Dulce Gonclaves will serve as corporate counsel and Stephane Henchoz will be director of finance.

Michael Forer, CEO of ADC Therapeutics, said: “The quality of individuals and depth of experience that we have been able to attract demonstrates the significant potential for our PBD-based ADCs. This expansion underlines the progress we have made since the Company was established in early 2002.”

1st October 2014

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics